Advanced

Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.

Ahrén, Bo LU ; Adner, N; Svartberg, J; Petrella, E; Holst, J J and Gutniak, M K (2002) In Diabetic Medicine 19(9). p.790-792
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Diabetic Medicine
volume
19
issue
9
pages
790 - 792
publisher
Wiley-Blackwell
external identifiers
  • pmid:12207819
  • wos:000177774900015
  • scopus:0036053256
ISSN
1464-5491
DOI
10.1046/j.1464-5491.2002.00657_1.x
language
English
LU publication?
yes
id
ee80cb2b-17db-4c91-8957-3eadfd700a7f (old id 110402)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12207819&dopt=Abstract
date added to LUP
2007-06-26 15:34:58
date last changed
2017-01-01 07:19:21
@article{ee80cb2b-17db-4c91-8957-3eadfd700a7f,
  author       = {Ahrén, Bo and Adner, N and Svartberg, J and Petrella, E and Holst, J J and Gutniak, M K},
  issn         = {1464-5491},
  language     = {eng},
  number       = {9},
  pages        = {790--792},
  publisher    = {Wiley-Blackwell},
  series       = {Diabetic Medicine},
  title        = {Anti-diabetogenic effect of the human amylin analogue, pramlintide, in Type 1 diabetes is not mediated by GLP-1.},
  url          = {http://dx.doi.org/10.1046/j.1464-5491.2002.00657_1.x},
  volume       = {19},
  year         = {2002},
}